"It did occur to me that the current yearly growth in procedures would not be growing as fast if our product becomes the market leader "
The YoY growth is driven by FDA approving use of TAVR in younger patient thus opening up the demographics rather than valve in valve replacement
CEO presentation - one of the best I have seen., page-25
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.71 |
Change
0.010(0.06%) |
Mkt cap ! $301.9M | |||
| Open | High | Low | Value | Volume |
| $16.00 | $16.01 | $15.49 | $3.254M | 230.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $15.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 700 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |